Wedbush raised the firm's price target on Kiniksa to $72 from $59 and keeps an Outperform rating on the shares. Arcalyst heads into Q2 earnings with continued commercial momentum following a strong start to the year, the firm says. Wedbush models Q2 Arcalyst revenue of $225.7MM, reflecting steady underlying demand and typical sequential progression. With only about 18% of the estimated 14,000 multiple-recurrence RP population currently on therapy and a continued shift toward earlier treatment, the firm sees meaningful runway for growth and views Kiniksa as on track to establish a durable multi-billion-dollar IL-1 franchise over time.
